TNF-α inhibitors: are they carcinogenic?

References

• BoymanOHeftiHPConradCNickoloffBSuterMNestleFOSpontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor αJ Exp Med200419973173614981113
   PubMed Web of Science ®Google Scholar
• O’ByrneKJDalgleishAGChronic immune activation and inflammation as the cause of malignancyBr J Cancer20018547348311506482
   PubMed Web of Science ®Google Scholar
• KimREmiMTanabeKCancer immunoediting from immune surveillance to immune escapeImmunology2000121114
   Web of Science ®Google Scholar
• YounesAAggarwallBBClinical Implications of the tumor necrosis factor family in benign and malignant hematologic disordersCancer20039845846712879461
   PubMed Web of Science ®Google Scholar
• JohrerKJankeKKrugmannJFieglMGreilRTransendothelial migration of myeloma cells is increased by tumor necrosis factor (TNF)-alpha via TNF receptor 2 and autocrine upregulation of MCP-1Clin Cancer Res2004101901191015041705
   PubMed Web of Science ®Google Scholar
• BergeronSBeaucheminMBertrandRCamptothecin and etoposide induced apoptosis in human leukemia cells is independent of cell death receptor 4 and 4 aggregation but accelerates tumor necrosis factor related apoptosis inducing ligand mediated cell deathMol Cancer Ther200431659166915634660
   PubMed Web of Science ®Google Scholar
• LeeNSCheongHJKimSJEx vivo purging of leukemia cells using tumor necrosis factor related apoptosis inducing ligand in hematopoietic stem cell transplantationLeukemia2003171375138312835727
   PubMed Web of Science ®Google Scholar
• Beyne-RauzyORecherCDastugueNTumor necrosis factor alpha induces senescence and chromosomal instability in human leukemic cellsOncogene2004237507751615326480
   PubMed Web of Science ®Google Scholar
• BaudVKarinMSignal transduction by tumor necrosis factor and its relativesTrendsCell Biol200111372377
   PubMed Web of Science ®Google Scholar
• AshkenaziATargeting death and decoy receptors of the tumour-necrosis factor superfamilyNat Rev Cancer2002242043012189384
   PubMed Web of Science ®Google Scholar
• SilmanAJPetrieJHazlemanBEvansSJLymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20 year follow up studyAnn Rheum Dis1988479889923207388
   PubMed Web of Science ®Google Scholar
• RadisCDKahlLEBakerGLEffect of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis: a 20 year followup studyArthritis Rheum199538112011277639809
   PubMed Web of Science ®Google Scholar
• MarietteXCazals-HatemDWarszawkiJLioteFBalandraudNSibiliaJLymphomas in rheumatoid arthritis patients treated with methotraxate: a 3 year prospective study in FranceBlood2002993909391512010788
   PubMed Web of Science ®Google Scholar
• LipskyPEvan der HeijdeDMSt ClairEWfor the Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study GroupInfliximab and methotraxate in the treatment of rheumatoid arthritisN Engl J Med20003431594160211096166
   PubMed Web of Science ®Google Scholar
• TsimberidouAMGilesFJDuvicMKurzrockRPilot study of etanercept in patients with relapsed cutaneous T-cell lymphomasJ Am Acad Dermatol20045120020415280837
   PubMed Web of Science ®Google Scholar
• TsimberidouAMWaddelowTKantarjianHMAlbitarMGilesFJPilot study of recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein (TNFR:Fc; Enbrel) in patients with refractory multiple myeloma: increase in plasma TNFα levels during treatmentLeuk Res20032737538012620287
   PubMed Web of Science ®Google Scholar
• KaneSAltschulerEKastRECrohn’s disease remission on bupropionGastroenterology20011211260126111706830
   PubMed Web of Science ®Google Scholar
• BaecklundEEkbomASparenPFelteliusNKlareskogLDisease activity and risk of lymphoma in patients with rheumatoid arthritis: a nested case – control studyBMJ19983171801819665898
   PubMed Web of Science ®Google Scholar
• ThomasEBrewsterDHBlackRJMacfarlaneGJRisk of malignancy among patients with rheumatic conditionsInt J Cancer20008849750211054684
   PubMed Web of Science ®Google Scholar
• BernsteinCNBlanchardJFKliewerEWajdaACancer risk in patients with inflammatory bowel disease: a population based studyCancer20019185486211241255
   PubMed Web of Science ®Google Scholar
• BrownSLGreeneMHGreshonSKEdwardsETBraunMMTumor necrosis factor antagonist therapy and lymphoma development. Twenty six cases reported to the Food and Drug AdministrationArthritis Rheum2002463151315812483718
   PubMed Web of Science ®Google Scholar
• OutlawWFleischerABloomfeldRLymphomatoid papulosis in a patient with Crohn’s disease treated with infliximabInflamm Bowel Dis20091596596618798565
   PubMed Web of Science ®Google Scholar
• WolfeFMichaudKLymphoma in rheumatoid arthritis: the effect of methotraxate and anti-tumor necrosis factor therapy in 18,572 patientsArthritis Rheum20045061740175115188349
   PubMed Web of Science ®Google Scholar
• BaecklundESundstromCEkbomALymphoma subtypes in patients with rheumatoid arthritis: increased proportion of diffuse large B cell lymphomaArthritis Rheum2003481543155012794821
   PubMed Web of Science ®Google Scholar
• GeborekPBladstromATuressonCTumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomasAnn Rheum Dis20056469970315695534
   PubMed Web of Science ®Google Scholar
• LeombrunoJPEinarsonTRKeystoneECThe safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse eventsAnn Rheum Dis2009681136114518753157
   PubMed Web of Science ®Google Scholar
• NairBRavalGMehtaPTNF-alpha inhibitor etanercept and hematologic malignancies: report of a case and review of literatureAm J Hematol2007821022102417654504
   PubMed Web of Science ®Google Scholar
• BaklandGNossentHAcute myelogenous leukemia following etanercept therapyRheumatology20034290090112826706
   PubMed Web of Science ®Google Scholar
• SabaNSKosseifiSGCharafEAAdalimumab-induced acute myelogenous leukemiaSouth Med J20081011261126219005432
   PubMed Web of Science ®Google Scholar
• Wegener’s Granulomatosis Etanercept Trial (WGET) Research GroupEtanercept plus standard therapy for Wegener’s granulomatosisN Engl J Med200535136115673801
   PubMed Web of Science ®Google Scholar
• De VriesHSvan OijenMGde JongDJSerious events with infliximab in patients with inflammatory bowel disease: a 9 year cohort study in the NetherlandsDrug Saf2008311135114419026030
   PubMed Web of Science ®Google Scholar
• St ClairEWvan der HeijdeDMSmolenJSCombination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized controlled trialArthritis Rheum200450113432344315529377
   PubMed Web of Science ®Google Scholar
• KeystoneECKavanaughAFSharpJTRadiographic, clinical, and functional outcomes of treatment with adalimiumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotraxate therapy: a randomized placebo controlled 52 week trialArthritis Rheum2004501400141115146409
   PubMed Web of Science ®Google Scholar
• van de PutteLBAAtkinsCMalaiseMEfficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failedAnn Rheum Dis20046350851615082480
   PubMed Web of Science ®Google Scholar
• BongartzTSuttonASweetingMBuchanIMattesonEMontoriVAnti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies. Systematic review and meta-analysis of rare harmful effects in randomized controlled trialsJAMA20062952275228516705109
   PubMed Web of Science ®Google Scholar
• WolfeFMichaudKBiologic treatment of rheumatoid arthritis and the risk of malignancy. Analyses from a large US observational studyArthritis Rheum2007562886289517729297
   PubMed Web of Science ®Google Scholar
• BianconeLOrlandoAKohnAInfliximab and newly diagnosed neoplasia in Crohn’s disease: a multicentre matched pair studyGut20065522823316120759
   PubMed Web of Science ®Google Scholar
• LichtensteinGRCohenRDFeagenBGSafety of infliximab and other Crohn’s disease therapies – TREAT registry data with nearly 15,000 patient-years of follow-upGastroenterology2006130A71
   Web of Science ®Google Scholar
• LeesCWAliAIThompsonAIThe safety profile of anti-tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient years follow upAliment Pharmacol Ther20092928629719132970
   PubMed Web of Science ®Google Scholar
• ColombelJFLoftusEVJrThe safety profile on infliximab in patients with Crohn’s disease: the Mayo clinic experience in 500 patientsGastroenterology2004126193114699483
   PubMed Web of Science ®Google Scholar
• RennardSIFogartyCKelsenSThe safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary diseaseAm J Respir Crit Care Med200717592693417290043
   PubMed Web of Science ®Google Scholar
• LeesCWIronsideJWallaceWASatsangiJResolution of non small cell lung cancer after withdrawal of anti-TNF therapyN Engl J Med200853932032118635444
   PubMed Web of Science ®Google Scholar
• ShaoLMChenMYCaiJTMeta-analysis: the efficacy and safety of certolizumab pegol in Crohn’s diseaseAliment Pharmacol Ther20092960561419183161
   PubMed Web of Science ®Google Scholar
• SandbornWJFeaganBGStoinovSCertolizumab pegol for the treatment of Crohn’s diseaseN Engl J Med200735722823817634458
   PubMed Web of Science ®Google Scholar
• SinghJANoorbaloochiSSinghGGolimumab for rheumatoid arthritis: a systematic reviewJ Rheumatol2010371096110420436075
   PubMed Web of Science ®Google Scholar
• StorageSSAgrawalHFurstDEDescription of the efficacy and safety of three new biologics in the treatment of rheumatoid arthritisKorean J Internal Med20102511720195397
   PubMedGoogle Scholar
• SmithKJSkeltonHGRapid onset of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis after starting tumor necrosis factor alpha receptor IgG1-Fc fusion complex therapyJ Am Acad Dermatol20014595395611712048
   PubMed Web of Science ®Google Scholar
• EssarACArbilAFayneSDoyleJAAcute development of multiple keratoacanthomas and squamous cell carcinomas after treatment with infliximabJ Am Acad Dermatol200450Suppl 5S75S7715097933
   PubMed Web of Science ®Google Scholar
• BurgeDEtanercept and squamous cell carcinomaJ Am Acad Dermatol20034935835912894101
   PubMed Web of Science ®Google Scholar
• LebwohlMBlumRBerkowitzENo evidence of increased risk of squamous cell carcinoma in patients with rheumatoid arthritis receiving etanercept for up to 5 yearsArch Dermatol200514186186416027301
   PubMedGoogle Scholar
• ChakravartyEFMichaudKWolfeFSkin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitorsJ Rheumatol2005322130213516265690
   PubMed Web of Science ®Google Scholar
• LedinghamJDeightonCUpdate of the British Society of Rheumatology: guidelines for prescribing TNF blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001)Rheumatology20054415716315637039
   PubMed Web of Science ®Google Scholar
• SaagKGTengGGPatkarNMfor the American College of RheumatologyAmerican College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying anti rheumatic drugs in rheumatoid arthritisArthritis Rheum20085976278418512708
   PubMed Web of Science ®Google Scholar